BCM
TENX icon

Bridgeway Capital Management’s Tenax Therapeutics TENX Stock Holding History

Bridgeway Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$718K Hold
44,900
– – 0.01% 765
2025
Q4 		$547K Buy
+44,900
New +$391K 0.01% 805

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bridgeway Capital Management's TENX Position: Q1 2026 in Review

Bridgeway Capital Management held its Tenax Therapeutics (TENX) position steady in Q1 2026 at 44,900 shares worth $718K. The position accounts for 0.01% of the portfolio, ranked #765.

Bridgeway Capital Management first reported a position in TENX in Q4 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Bridgeway Capital Management held 44,900 shares of Tenax Therapeutics worth $718K as of Q1 2026.
  • Bridgeway Capital Management left its Tenax Therapeutics share count unchanged in Q1 2026.
  • Tenax Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #765 holding.
  • Bridgeway Capital Management first reported a position in Tenax Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.